Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
General requirements for all groups (Arms 1, 2, and 3):
- People whose veins are suitable for an apheresis procedure (a process where blood is drawn out, filtered, and returned to the body)
- People with a general health and activity level rated as ECOG 0–2 (meaning they are fully active to capable of basic self-care — confirm with trial site)
- People with normal blood levels of potassium, calcium, and magnesium
- People with a testosterone level above 1.7 nmol/L
- People with a haemoglobin (red blood cell) level above 90 g/L
- People with a platelet count above 50 x 10⁹/L
- People with a white blood cell count above 1 x 10⁹/L
- People with bilirubin (a liver marker) below 1.4 times the upper limit of normal (except for people with a condition called Gilbert's disease)
- People with liver enzyme levels (ALAT or ASAT) below 2.4 times the upper limit of normal
- People with a creatinine level (a kidney marker) below 177 µmol/L
Arm 1 — Metastatic prostate cancer (at least one of the following):
- People with a PSA level above 100 ng/mL
- People with bone metastases that are considered high-risk for prostate cancer, regardless of PSA level
Arm 2 — Rising PSA after prostate removal surgery (all three must apply):
- People who have had their prostate surgically removed
- People with a PSA level above 0.2 ng/mL
- People whose PSA level is doubling in less than 18 months
Arm 3 — Healthy control group (both must apply):
- People who were previously healthy with no ongoing medications
- People with no history of cancer
Who may not be able to join:
- People with any other active cancer diagnosis or health factors that increase the risk of the apheresis procedure
- People who weigh less than 50 kg
- People who have had medical or surgical castration (hormone-suppressing treatment) in the past 6 months
- People who have received anti-androgen (hormone-blocking) treatment in the past 6 months
- People with a history of heart attack, stroke, chronic heart failure, atrial fibrillation, or multiple episodes of deep vein thrombosis (blood clots)
- People with a resting heart rate below 45 beats per minute
- People with a systolic blood pressure below 100 mmHg
- People with an ongoing diagnosed chronic inflammatory condition
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andreas Josefsson, MD, PhD, Department of surgical and perioperative sciences, Urology, Umeå University
Phone: +46 70 3805395
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identify circulating tumor cells (CTC) for molecular characterization; Differentiated gene expression in CTCs before and after treatment start; Phenotypical changes of immune cells due to anti-androgen treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.